Novartis Pharmaceuticals Corp. and Proctor & Gamble Pharmaceuticals, Inc. have entered into an agreement for the co-promotion and further development of darifenacin (Enablex) extended-release tablets for the treatment of overactive bladder in the United States.
Novartis Pharmaceuticals Corp. and Proctor & Gamble Pharmaceuticals, Inc. have entered into an agreement for the co-promotion and further development of darifenacin (Enablex) extended-release tablets for the treatment of overactive bladder in the United States. Novartis will continue to record revenues for the drug and will pay royalties to Proctor & Gable based on the product's performance.
In related news, Indevus Pharmaceuticals, Inc. has announced the closing of a previously announced sale of the marketing rights for trospium chloride (Sanctura) from Odyssey Pharmaceuticals, Inc. to Esprit Pharma Holding Co., Inc. Esprit Pharma is a recently formed, privately held pharmaceutical company.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.